这项研究旨在评估MR引导的立体定向激光消融(SLA)治疗小儿脑肿瘤的安全性和有效性。
回顾性分析了来自17个北美中心的数据。临床,技术,收集并分析了2008年至2016年接受SLA诊断为脑肿瘤的儿科患者的影像学资料.
共86例患者(平均年龄12.2±4.5岁),有76例低级别(I或II)和10例高级别(III或IV)肿瘤。肿瘤位置包括叶部(38.4%),深(45.3%),和小脑(16.3%)隔室。平均随访时间为24个月(中位数为18个月,范围3-72个月)。在最后一次随访中,在有随访数据的80.6%患者中,接受SLA治疗的肿瘤体积减少.与低度肿瘤患者相比,高度肿瘤患者在SLA治疗后更可能具有不变或更大的肿瘤大小(OR7.49,p=0.0364)。在SLA治疗后,90.4%和86.7%的患者不需要后续手术和辅助治疗,分别。高级别肿瘤患者在SLA治疗后更有可能接受后续手术(OR2.25,p=0.4957)和辅助治疗(OR3.77,p=0.1711),没有达到意义。共报告了23例患者的29例急性并发症,包括导管错位(n=3)。颅内出血(n=2),短暂性神经功能缺损(n=11),永久性神经功能缺损(n=5),症状性病灶周围水肿(n=2),脑积水(n=4),死亡(n=2)。在长期随访中,据报道,3例患者的神经心理学测试结果恶化。SLA前肿瘤体积,肿瘤位置,激光轨迹的数量,并且所产生的病变数量并未显著增加并发症的风险;然而,产生的病变体积每增加1-cm3,并发症的几率增加14%(OR1.14,p=0.0159).
SLA是有效的,小儿脑肿瘤的微创治疗选择,虽然并非没有风险。限制所产生的热损伤的体积可有助于降低并发症的发生率。
This
study aimed to assess the safety and efficacy of MR-guided stereotactic laser ablation (
SLA) therapy in the treatment of pediatric brain tumors.
Data from 17 North American centers were retrospectively reviewed. Clinical, technical, and radiographic data for pediatric patients treated with
SLA for a diagnosis of brain tumor from 2008 to 2016 were collected and analyzed.
A total of 86 patients (mean age 12.2 ± 4.5 years) with 76 low-grade (I or II) and 10 high-grade (III or IV) tumors were included. Tumor location included lobar (38.4%), deep (45.3%), and cerebellar (16.3%) compartments. The mean follow-up time was 24 months (median 18 months, range 3-72 months). At the last follow-up, the volume of SLA-treated tumors had decreased in 80.6% of patients with follow-up data. Patients with high-grade tumors were more likely to have an unchanged or larger tumor size after
SLA treatment than those with low-grade tumors (OR 7.49, p = 0.0364). Subsequent surgery and adjuvant treatment were not required after
SLA treatment in 90.4% and 86.7% of patients, respectively. Patients with high-grade tumors were more likely to receive subsequent surgery (OR 2.25, p = 0.4957) and adjuvant treatment (OR 3.77, p = 0.1711) after SLA therapy, without reaching significance. A total of 29 acute complications in 23 patients were reported and included malpositioned catheters (n = 3), intracranial hemorrhages (n = 2), transient neurological deficits (n = 11), permanent neurological deficits (n = 5), symptomatic perilesional edema (n = 2), hydrocephalus (n = 4), and death (n = 2). On long-term follow-up, 3 patients were reported to have worsened neuropsychological test results. Pre-
SLA tumor volume, tumor location, number of laser trajectories, and number of lesions created did not result in a significantly increased risk of complications; however, the odds of complications increased by 14% (OR 1.14, p = 0.0159) with every 1-cm3 increase in the volume of the lesion created.
SLA is an effective, minimally invasive treatment option for pediatric brain tumors, although it is not without risks. Limiting the volume of the generated thermal lesion may help decrease the incidence of complications.